This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth (UNH) to Post Q1 Earnings: What to Expect
by Zacks Equity Research
UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.
Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium
by Zacks Equity Research
Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
by Zacks Equity Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.
Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.
CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales
by Zacks Equity Research
CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.
BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
by Zacks Equity Research
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
by Zacks Equity Research
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.
What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?
by Zacks Equity Research
In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.
Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.
What's in Store for Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.
Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
by Zacks Equity Research
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.